ASLAN Pharmceuticals is pleased to announce the designation as an Orphan drug of its pan-HER inhibitor varlitinib (ASLAN001) by the US Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for gastric cancer.

Varlitinib previously received Orphan Drug Designation for cholangiocarcinoma in August 2015.

For more details, please refer to the press release in English or Chinese.